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 Abstract 
Purpose: ​To evaluate the efficacy and survival rates of same session ab interno trabeculectomy with the 
trabectome and Ahmed glaucoma valve implant (AT) in comparison to the Ahmed glaucoma valve alone (A). 
Method​: A total of 107 eyes undergoing primary glaucoma surgery were enrolled in this retrospective 
comparative case series, including 48 eyes which underwent AT and 59 eyes which received ​A alone​. 
Participants were identified using the procedural terminology codes, and their medical records were reviewed. 
The primary outcome measure was surgical success, defined as intraocular pressure (IOP) > ​5 mmHg, ≤ 21 
mmHg,​ and IOP reduction ≥ 20% from baseline at two consecutive visits after three months, no reoperation 
for glaucoma. Secondary outcome measures were IOP, the number of glaucoma medications, incidence of a 
hypertensive phase, and best corrected visual acuity (BCVA). 
Results: ​The cumulative probability of success at one year was 70% in AT, and 65% in A (p=0.85). IOP 
decreased significantly from 26.6 ± 10.1 mmHg at baseline to 14.7 ± 3.3 mmHg at the final follow-up in AT (p= 
0.001). The corresponding numbers for A were 28.8 ± 10.2 and 16.7 ± 4.9, respectively (p= 0.001). The final 
IOP was significantly lower in AT (p= 0.022). The number of medications at baseline was comparable in both 
groups (2.6 ± 1.2 in AT and 2.5 ± 1.3 in A, p=0.851). Corresponding number at 1 year visit was 1.2±2 in AT and 
2.8±1.8 in A (p=0.001). 
The incidence of a hypertensive phase was 18.7% in AT and 35.5% in A (p=0.05). HP resolved in only 30% of 
eyes. The criteria for HP resolution were fulfilled in 9 eyes (30%). There was no difference in the rate of 
resolution of the hypertensive phase between AT and A (33.3% and 28.5%, respectively, p=0.67). 
Conclusion​: Ahmed glaucoma valve implant with same session trabectome surgery significantly decreased the 
rate of the hypertensive phase and postoperative IOP as well as the number of glaucoma medications. 
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 Introduction 
Trabeculectomy and glaucoma drainage devices (GDD) are common surgical interventions for advanced 
glaucomas ​[1–3]​. Concerns about bleb-related complications along with studies that indicated an equal or 
even higher success rate of glaucoma drainage devices have contributed to their increased use ​[2, 4]​. The shift 
in practice pattern from trabeculectomy to GDDs in severe glaucoma is evidenced by a 43% decrease in the 
number of trabeculectomies and a 184% increase in GDDs in the United States between 1995 and 2004 ​[5, 6]​. 
The two most common GDDs in the US are non-valved Baerveldt implants (BI, Advanced Medical Optics, Santa 
Ana, California, USA) and the valved Ahmed valve implants (AGV, New World Medical Inc, Rancho Cucamonga, 
California, USA) ​[7]​. While BIs require an intraoperative flow restriction to allow capsule formation around the 
plate, AGVs offer an immediate intraocular pressure control (IOP) ​[8, 9]​. Although the average IOP following 
AGV is about 1.85 mmHg higher than in BI, a comparable success rate, fewer postoperative complication rates, 
and ease of handling are advantages of AGV over BI ​[4]​. A downside of AGV is an increased rate of a 
hypertensive phase (HP) that can persist if not managed aggressively ​[10]​ with an incidence that ranges from 
30% to 82% and starts one to 13 weeks postoperatively ​[10–13]​. It has been speculated that early contact of 
aqueous inflammatory mediators with Tenon’s capsule and the conjunctiva or early stretch ​[14]​ of the forming 
capsule may lead to this ​[10, 15, 16]​. The management strategies for HP include early initiation of aqueous 
suppressant treatment after AGV implantation ​[16]​, steroid injection at the time surgery ​[17]​, antimetabolites, 
digital massage ​[18]​, bleb needling, and surgical excision of the bleb ​[8]​.​ While GDDs bypass the conventional 
outflow, the Trabectome surgical system (NeoMedix, Tustin, CA, USA) enhances the conventional outflow ​[19]​. 
It has a long track record of safety and efficacy in different types and severity of glaucoma ​[20, 21]​.  
We hypothesized that the addition of trabectome surgery not only compensates for a higher IOP in AGVs 
compared to BI but also decreases the incidence of hypertensive phase by reducing the levels of aqueous 
humor inflammatory mediators surrounding the plate and overlying tissue.  
Methods  
The protocol of this study was approved by the Institutional Review Board of the University of Pittsburgh 
Human Subjects Research Committee and adhered to the tenets of the Declaration of Helsinki and regulations 
of the Health Insurance Portability and Accountability Act.  
Patients who underwent either ​AGV​ with trabectome surgery (AT) or AGV alone (A) between 2008 and 2015 
were identified using Current Procedural Terminology codes. Four glaucoma fellowship-trained surgeons 
performed the procedures. Patients older than 20 years with medically uncontrolled IOP were included in this 
study. Exclusion criteria were a history of uveitic glaucoma, prior ocular surgery (except uncomplicated 
phacoemulsification) and ​neovascular​ glaucoma. Data were collected from patients’ electronic medical record 
and included basic demographic information, type of glaucoma and preoperative diagnosis, preoperative IOP 
and the number of glaucoma medications, baseline best corrected visual acuity (BCVA), type of operation, as 
well as the postoperative data for IOP, ​number​ of medications, and BCVA. 
The primary outcome measure was success defined as IOP > 5 mmHg, ≤ 21 mmHg and ≥ 20% reduction of IOP 
from baseline at two consecutive visits after three months, no need for further glaucoma surgery ​[22]​. Eyes 
that had not failed and were not receiving glaucoma medical therapy were considered complete successes, 
 and those requiring adjunctive medical therapy were defined as qualified successes. The secondary outcome 
measures were IOP, the rate of a hypertensive phase, BCVA, and the number of medications. 
The hypertensive phase (HP) was defined as an IOP above 21 mmHg during the first 3 months after surgery 
(with or without medications) after reduction of IOP to less than 22 mmHg was achieved within the first week 
postoperatively ​[10]​. High IOP must not have been secondary to tube occlusion, malposition, or valve 
dysfunction. A valve dysfunction was diagnosed if the IOP did not fall immediately after the operation. The 
resolution of hypertensive phase was defined as an IOP < 22 mmHg and a reduction of the IOP by 3 mmHg 
with the same number of medications or less, or a reduction of at least one medication with a change of IOP < 
3 mmHg ​[10]​. In all cases, the IOP was measured with a Goldmann ​applanation​ tonometer (GAT;​ Haag-Streit, 
Konig, Switzerland) at 1 day, 1 week, 4 ±1 week, 2-4 months, 5-7 months, 8-10 months, and 11-13 months.​ If 
more than one visit was found at these intervals, the visit closest to month 6, 9, or 12 was chosen. 
Surgical technique 
In AT, the Trabectome (NeoMedix, Tustin, CA, USA) surgery was performed first as described in the following. 
The patient’s head was tilted away, and the microscope was tilted toward the surgeon by about 30˚. A 
temporal 1.6 mm clear corneal incision that was iris-parallel was created, and the ​handpiece​ was advanced 
into the anterior chamber. Under direct gonioscopic view, the tip of the trabectome was engaged with the 
trabecular​ meshwork (TM) at the nasal angle; ablation was started and continued for 60˚  counterclockwise 
followed by a 60˚  clockwise move to opposite direction for an approximately 120˚ TM ablation. The ​handpiece 
was withdrawn from the anterior chamber, and the incision was hydrated to seal. 
In AGV, a 7-0 traction suture was placed through the supratemporal perilimbal cornea. An eight millimeter 
long, limbus-parallel incision through the conjunctiva and Tenon’s capsule, five millimeters posterior to the 
limbus was created in the supratemporal quadrant, and Tenon’s capsule was dissected away from the sclera 
with Westcott scissors to provide space for the plate insertion. The device (Ahmed glaucoma drainage implant, 
model FP7, New World Medical, Rancho Cucamonga, California) was primed with 2 ml of buffered saline 
solution (BSS) and gently pushed through the incision into the ​subtenon​ space. The plate was secured to the 
sclera 10 mm posterior to the limbus using an 8-0 nylon suture. The tube was trimmed bevel up with an 
estimated intracameral length of 2 mm. A 23-gauge needle was inserted into the anterior chamber bevel up, 
parallel to the iris and 1 mm posterior to the limbus. The tube was passed through the tunnel into the anterior 
chamber and secured to the sclera with a 10-0 nylon suture. A 5x8 mm scleral patch graft was placed over the 
tube. Tenon’s capsule and the conjunctiva were closed using a running 10-0 nylon mattress suture. The 
postoperative regimen consisted of moxifloxacin eye drops four times daily for one week and ​1% prednisolone 
acetate four times per day ​for one month followed by gradual taper.  
Statistical analysis 
All analyses were performed using SPSS software (SPSS Statistics for Windows, Version 22, Armonk, NY, IBM 
Corporation) to describe data, frequency, and percent; ​mean±SD​, median, and range were used. To evaluate 
the baseline differences between two groups, we used ANOVA, Kruskal–Wallis, Chi-Square, and Fisher exact 
test. To compare the rate of changes between two groups during the study follow-ups, we used interaction 
analysis within a linear mixed model. To compare the results between the groups adjusted for the baseline 
values, we used an Analysis of Covariance (ANCOVA). The difference in IOP and the ​number​ of glaucoma 
medications between two groups were assessed by Mann-Whitney test and independent T-test. To analyze 
 the survival of subjects in the groups, Kaplan-Meier survival plots were constructed and compared using the 
log-rank test. Statistical significance was defined as ​p​≤ 0.05. Success was defined as IOP ≤21 mmHg, > 5 mmHg, 
and a >20% reduction from baseline with no need for further surgery. 
Results  
A total of 107 eyes were included in this study consisting of 48 AT and 59 ​A​. The baseline patient                    
demographics are presented in Table 1. The mean age of the study participants was 64.4±15.6 years in AT and                   
69.3±15.1 years in A (0.107). Thirty patients (29.4%) underwent phacoemulsification at the time of glaucoma               
surgery, 12 eyes (27.9%) in AT and 18 Eyes (30.5%) in A (0.776). Primary open-angle glaucoma was the most                   
common diagnosis in both groups (79.2% and 71.2​% in AT and A, respectively, p=0.680). There were no                 
significant differences between the study groups regarding gender, preoperative intraocular pressure,           
baseline number of glaucoma medications, and type of glaucoma (Table 1). 
The Kaplan-Meier survival curves (Figure 1) indicated a mean duration of survival ​of​ 10.65±0.41 months in AT 
group and 10.48 ± 0.46 in A with no statistically significant difference between two groups (​LogRank​= 0.03, ​p= 
0.85).​ The cumulative probability of success at 6 months and 12 months was 77.5% and 70% in AT, and 75% 
and 65% in A. The complete success was 56.2% in AT and 13.5% in A. At the final follow-up visits, 27 eyes in AT 
and 8 eyes in A did not use glaucoma medications. In the subgroup analysis, the mean survival duration was 
10.61 ± 0.7 months ​in AT with phacoemulsification versus ​10.4 ± 1.23 ​months in A with phacoemulsification 
(​LogRank= 0.39, p= 0.53​). Corresponding values for glaucoma surgery alone were ​10.6 ± 0.51​ and ​10.38 ± 0.55 
in AT​ and A, respectively (​LogRank= 0.002, p= 0.96​, Figure 1).  
IOP was decreased significantly from 26.6 ± 10.1 mmHg at baseline to 14.7 ± 3.3 mmHg at final follow-up in AT 
(p= 0.001, Figure 2). The corresponding numbers for A were 28.8 ± 10.2 and 16.7 ± 4.9, respectively (p= 0.001, 
Table 2). During the 1-year follow-up, 6 (12.5%) patients in AT and 5 (8.4%) patients in A group experienced 
hypotony, respectively (p=0.12).  
IOP was significantly lower in AT at the final follow-up visit (p= 0.022). Eyes in AT experienced an 11.49 ± 8.8 
mmHg reduction in IOP one year after the surgery compared to a 12.17 ± 10.16 mmHg reduction in A (p= 
0.830, Figure 2). IOP was comparable on day one between AT with phacoemulsification and AT (10.3±7.1 
mmHg versus 12.1±8.7 mmHg, p= 0.63). A combined with phacoemulsification had a significantly higher IOP 
on day one compared to A (18.2±9.4 versus 13.3±8.4, ​p=0.004). 
Nine eyes in AT (18.7%) and 21 eyes in A (35.5%) experienced a hypertensive phase within three months of 
operation (0.51). Logistic regression analyses were performed to explore what factors were associated with HP 
development. Results indicated that the preoperative IOP was significant in the multivariate outcome (Table 
3). The criteria for HP resolution were fulfilled in 9 eyes (30%). There was no difference in the rate of HP 
resolution between AT and A ​(​33.3% and 28.5%, respectively, p=0.67). 
The baseline number of glaucoma medications was 2.6 ± 1.2 in AT and 2.5 ± 1.3 in A (p=0.851). At the final 
follow-up visit, the number of glaucoma medications was 1.2 ± 1.1 drops in AT and 2.8±1.8 in A (p=0.001). 
While there was a ​significant​ reduction in the number of medications in AT (p= 0.01), glaucoma medications 
remained unchanged at one-year follow-up visit in A (p=0.21). 
 The mean BCVA at the baseline was 0.56 ± 0.56 ​logMAR​ in AT and 0.71 ± 0.88 ​logMAR​ in A (p=0.122). 
Corresponding numbers for final follow-up visit were 0.62±1.07 ​logMAR and 0.83±0.97​ ​logMAR, respectively 
(p= 0.468).  
Discussion 
This study evaluated the effect of same-session Trabectome surgery on the outcomes of Ahmed glaucoma 
valve implantation. AT and A were both effective in reducing IOP. The IOP reduction of 40% at the 1-year 
follow-up was similar to previous reports ​[2, 7, 8, 17]​. Adding trabectome surgery led to a significantly lower 
IOP with fewer glaucoma medications throughout the postoperative follow-up visits. Also, a same-session 
trabectome surgery blunted potentially dangerous post-phacoemulsification IOP spikes, consistent with our 
previous studies on this subject ​[23]​.  
The IOP after GDD implantation has typically two phases: 7 to 10 days of relative hypotony that may be 
followed by the rise of intraocular pressure above 21 mmHg during the hypertensive phase ​[24]​. This 
sequence was first described for the Molteno device and was addressed by a complete intraoperative tube 
ligation to prevent aqueous from negatively impacting the bleb maturation ​[25]​. More recent studies of these 
devices do not describe a significant hypertensive phase ​[9, 26–28]​.​ Aqueous humor of patients with glaucoma 
contains a ​high​ concentration of tissue growth factor ​b​ (TGF-​b​), which has a substantial regulatory effect on 
the extracellular matrix macromolecules and synthesis of matrix protein as well as an ​inhibitory​ effect on 
degradative proteolytic enzymes ​[15]​.  
The incidence of a hypertensive phase in our study was 28.1%, lower but not inconsistent with previous 
studies ​[10, 16, 24]​. We observed significantly fewer cases of hypertension phase in the AT group with only 
18.7%. Trabectome surgery enhances the physiologic outflow by removing the trabecular meshwork and 
reduces the inflammatory cytokines and stretch in the AGV bleb. In another study with the same rationale as 
ours, Pakravan et al. randomized eyes that underwent AGV to either starting aqueous suppressants once 
postoperative IOP raised to 10 mmHg or routine follow-up where glaucoma medications were commenced if 
deemed necessary by the surgeon ​[16]​.​ The incidence of HP in the former group was 23% compared to 60% in 
the routine follow-up. The results of our study match this finding and corroborate the role of aqueous 
inflammatory mediators and capsule stretch in promoting hypertensive phase. 
Another explanation for a ​lower​ incidence of HP in AT is the effect of trabectome surgery itself. Trabectome is 
shown to decreases IOP by 30% from the baseline and reduces the number of glaucoma medications by 38% 
at seven years follow-up ​[20, 29]​.  
HP has been described in up to 80% after AGV, but few studies have evaluated the clinical course of this 
phenomenon ​[10, 11, 24]​. Most reports on post-GDD hypertensive phase showed relative reversibility of IOP 
in a ​significant​ number of patients, hence the term hypertensive “phase.” However, most of these studies 
based their conclusion on IOP reduction without considering the effect of glaucoma medications on IOP. To 
address this issue, we incorporated changes in both IOP and glaucoma medications in our definition of HP 
resolution. Applying this definition, HP resolved in 30% of the cases, which agrees with the 28% reported by 
Nouri-Mahdavi and Caprioli ​[10]​. Development of high IOP in the early postoperative period is an unfavorable 
prognostic factor and indicates the vigilant monitoring of IOP and continuation of medications. 
 There are several limitations to this study. Due to its retrospective nature, patients were not randomized to 
each treatment group. Although applying different matching methods like coarsened exact ​[23, 30, 31]​ and 
propensity score matching ​[28]​ that we used in our previous studies could reduce the bias due to confounding 
variables, we were unable to use them here due to relatively small sample size. Additionally, this study was 
conducted at a single tertiary academic center and cannot easily be generalized to other practices. 
In summary, we found that Ahmed glaucoma valves with same session trabectome surgery significantly 
decreased the rate of a hypertensive phase, and was associated with a lower​ postoperative​ IOP and fewer 
glaucoma medications. 
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 Figures and Tables 
Table 1 
Table 1.​ ​Baseline patients characteristics. 
  
Total 
Group 
P   AT A 
Age Mean ± SD 67.1 ± 15.4 64.4 ± 15.6 69.3 ± 15.1 0.107† 
 Median (range) 68.5 (25 to 95) 64 (25 to 95) 74 (31 to 94)  
BCVA Mean ± SD 0.71 ± 0.74 0.56 ± 0.56 0.87 ± 0.88 0.057‡ 
 Median (range) 0.44 (0 to 3.3) 0.3 (0 to 2.8) 0.51 (0 to 3.3)  
IOP Mean ± SD 27.4 ± 10.3 26.6 ± 10.1 28.8 ± 10.2 0.121† 
 Median (range) 26 (8 to 56) 23.5 (9 to 56) 28 (8 to 56)  
Medications Mean ± SD 2.6 ± 1.3 2.6 ± 1.2 2.6 ± 1.4 0.814‡ 
 Median (range) 3 (0 to 7) 3 (0 to 5) 3 (0 to 7)  
Sex F 60 (56.1%) 25 (52.1%) 35 (59.3%) 0.453* 
 M 47 (43.9%) 23 (47.9%) 24 (40.7%)  
Phacoemulsification No 72 (70.6%) 31 (72.1%) 41 (69.5%) 0.776* 
 Yes 30 (29.4%) 12 (27.9%) 18 (30.5%)  
Type of glaucoma POAG 80 (74.8%) 38 (79.2%) 42 (71.2%) 0.680** 
 CACG 11 (10..2%) 4 (8.3%) 7 (11.8%)  
 PXF 10 (9.3%) 4 (6.8%) 6 (10.1%)  
 Other 6 (5.7%) 2 (4.1%) 4 (6.7%)  
† Based on ​t​-test., ‡ Based on Mann-Whitney test., * Based on Chi-Square test., ** Based on Fisher exact test. 
 
 
 
 
 
 
  
 Table 2 
Table 2.​ Comparison of postoperative changes in intraocular pressure between AT and A. 
Time Total 
Group 
Diff 
95% CI 
P† VarDiff P‡ AT A   
Baseline 27.4 ± 10.3 26.6 ± 10.1 28.8 ± 10.2 3.2 -0.8 7.2 0.12 0.843 
Day 1 12.8 ± 10.6 11 ± 6.9 14.5 ± 12.8 3.5 -0.7 7.7 0.09 <0.001 
 -14.4 ± 14.78 -14.65 ± 10.4 -14.1 ± 17.8 0.5 -5.5 6.4 0.87 0.001 
Day 7 12.1 ± 7.6 11 ± 6.7 13 ± 8.3 2 -1.1 5 0.2 0.24 
 -15.5 ± 11.78 -14.61 ± 9.1 -16.2 ± 13.6 -1.7 -6.4 3.1 0.48 <0.001 
Month 1 17.3 ± 7.9 16.4 ± 7 18 ± 8.6 1.7 -1.6 4.9 0.3 0.26 
 -9.89 ± 11.18 -9.14 ± 9.6 -10 ± 12.3 -1.4 -5.9 3.2 0.54 0.25 
Month 3 15.4 ± 6.6 14.7 ± 5.4 16.1 ± 7.5 1.4 -1.3 4.1 0.31 0.03 
 
-12.64 ± 11.92 -11.02 ± 11.4 -14.1 ± 12. -3.1 -8.1 1.9 0.21 0.49 
Month 6 17.1 ± 6.6 15.9 ± 4.8 18.8 ± 8.2 2.9 -0.2 6 0.06 0 
 -9.83 ± 10.76 -9.49 ± 10.51 -10.3 ± 11.2 -0.8 -6.1 4.4 0.75 0.55 
Month 12 15.7 ± 4.3 14.7 ± 3.3 16.7 ± 4.9 2 0.1 3.9 0.04 0.02 
 -11.75 ± 9.53 -10.49 ± 8.8 -12.9 ± 10.1 -2.5 -6.9 1.9 0.26 0.83 
Diff: Difference.​ ​VarDiff: Variation difference.​ † Based on ​t​-test. ‡ Based on Leven’s test 
 
 
  
 Table 3 
Table 3:​ Logistic regression analyses of baseline predictors of an ocular hypertensive phase with AGV 
Implantation.  
Variables B coefficient P-value 
Baseline IOP 1.04 0.05 
Age 0.98 0.35 
Gender 2.09 0.13 
Phaco combination 0.56 0.32 
IOP: intraocular pressure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1
 
Figure 1:​ A​)​ ​Kaplan-Meier survival plots for AT and A with success defined as a final IOP of ≤ 21 mmHg and a 
20% reduction from baseline. Success rates of AT and A was similar in both groups. B) survival plots of AT and 
A for subgroup analysis separated by B) glaucoma surgery alone (upper right) and C) same session 
phacoemulsification (lower right). 
 
  
 Figure 2 
 
Figure 2: ​IOP in AT and A. A​)​ IOP in AT was significantly lower than A thorough postoperative follow-up visits 
(asterisks indicate statistically significant difference).  B) AT + ​phaco​ had a lower IOP on day one compared to 
subsequent ​IOPs​ while IOP was higher on day one in ​A+phaco​. ​C) AT and AT as standalone procedures. 
Mean±95% confidence interval.  
 
